ATE448785T1 - Behandlung von entzündlicher darmerkrankung - Google Patents

Behandlung von entzündlicher darmerkrankung

Info

Publication number
ATE448785T1
ATE448785T1 AT05846549T AT05846549T ATE448785T1 AT E448785 T1 ATE448785 T1 AT E448785T1 AT 05846549 T AT05846549 T AT 05846549T AT 05846549 T AT05846549 T AT 05846549T AT E448785 T1 ATE448785 T1 AT E448785T1
Authority
AT
Austria
Prior art keywords
inflammatory bowel
bowel disease
treatment
animal
analog
Prior art date
Application number
AT05846549T
Other languages
English (en)
Inventor
David Old
Danny Dinh
Karen Kedzie
Daniel Gil
Wha Im
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE448785T1 publication Critical patent/ATE448785T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05846549T 2004-11-29 2005-11-22 Behandlung von entzündlicher darmerkrankung ATE448785T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/999,451 US7326716B2 (en) 2003-06-06 2004-11-29 Treatment of inflammatory bowel disease
PCT/US2005/042467 WO2006058080A1 (en) 2004-11-29 2005-11-22 Treatment of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
ATE448785T1 true ATE448785T1 (de) 2009-12-15

Family

ID=35903405

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05846549T ATE448785T1 (de) 2004-11-29 2005-11-22 Behandlung von entzündlicher darmerkrankung

Country Status (10)

Country Link
US (1) US7326716B2 (de)
EP (1) EP1817033B1 (de)
AT (1) ATE448785T1 (de)
AU (1) AU2005309622A1 (de)
BR (1) BRPI0518690A2 (de)
CA (1) CA2589438C (de)
DE (1) DE602005017815D1 (de)
DK (1) DK1817033T3 (de)
ES (1) ES2334374T3 (de)
WO (1) WO2006058080A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700627B2 (en) * 2006-07-26 2010-04-20 Allergan, Inc. Therapeutic substituted lactams
CN102065864B (zh) * 2008-06-23 2012-11-21 日本新药株式会社 炎性肠病治疗剂
EP2198879A1 (de) 2008-12-11 2010-06-23 Institut Curie CD74-modulierender Wirkstoff zur Regulierung der Dendritenzellmigration und Verfahren zur Untersuchung der Bewegungsfähigkeit einer Zelle
EP2199273B1 (de) 2008-12-18 2018-02-21 Agfa Nv Polymerisierbare Fotoinitiatoren und strahlungshärtbare Zusammensetzungen
CN102428112B (zh) 2009-05-18 2014-01-08 爱克发印艺公司 可聚合的聚合物光引发剂和辐射可固化组合物
WO2011047048A1 (en) 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
ES2565984T3 (es) 2010-10-20 2016-04-08 Agfa Graphics N.V. Fotoiniciadores polimerizables para composiciones curables por LED
CA2890034A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2868650B1 (de) 2013-10-30 2018-08-08 Agfa Nv Synthese von Acetalverbindungen unter Verwendung von zwitterionischen Katalysatoren
EP4706758A3 (de) 2019-05-21 2026-05-06 Ardelyx, Inc. Verfahren zur hemmung des phosphattransports

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
SE520947C2 (sv) * 2002-01-18 2003-09-16 Aneo Ab Ventilarrangemang för blandning av två medier
WO2004029581A2 (en) * 2002-09-26 2004-04-08 The Children's Hospital Of Philadelphia Method of determining surface binding capacity
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
RU2311409C2 (ru) 2003-01-10 2007-11-27 Ф.Хоффманн-Ля Рош Аг Производные 2-пиперидона в качестве агонистов простагландина
US6977260B2 (en) * 2004-01-22 2005-12-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US6747037B1 (en) * 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
DE10341727A1 (de) * 2003-09-10 2005-04-28 Starck H C Gmbh Reinigung von Ammoniummetallat-Lösungen
AU2005252171A1 (en) 2004-06-04 2005-12-22 Allergan, Inc. Piperidinyl prostaglandin analogs as ocular hypotensive agents

Also Published As

Publication number Publication date
CA2589438C (en) 2014-07-22
US7326716B2 (en) 2008-02-05
AU2005309622A1 (en) 2006-06-01
WO2006058080A1 (en) 2006-06-01
US20050171062A1 (en) 2005-08-04
ES2334374T3 (es) 2010-03-09
DE602005017815D1 (de) 2009-12-31
EP1817033B1 (de) 2009-11-18
EP1817033A1 (de) 2007-08-15
BRPI0518690A2 (pt) 2008-12-02
CA2589438A1 (en) 2006-06-01
DK1817033T3 (da) 2010-03-08

Similar Documents

Publication Publication Date Title
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA200601239A1 (ru) Замещённые хинолиновые соединения
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
MA31086B1 (fr) Formulations de doses unitaires et procedes de traitement d'une thrombose avec un inhibiteur oral du facteur xa.
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
ECSP066684A (es) Nitrooxiderivados de prostaglandinas
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
UY28280A1 (es) 2- hidroxi - 3- diaminoalcanos de benzamida
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
EP1732484A4 (de) Ophthalmisches implantat zur behandlung von glaukom
EP1689713A4 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
UY28279A1 (es) Fenacilo 2 -hidroxi - 3 - diaminoalcanos
ATE448785T1 (de) Behandlung von entzündlicher darmerkrankung
ATE491453T1 (de) Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
ATE424208T1 (de) Proteinkinaseinhibitoren
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
EA200601607A1 (ru) Сульфонамидные соединения для лечения нейродегенеративных расстройств
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
CY1106385T1 (el) Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties